Pimavanserin for Parkinson's Disease psychosis: Effects stratified by baseline cognition and use of cognitive-enhancing medications.
Alberto J EspayMichael T GuskeyJames C NortonBruce CoateJoaquin A VizcarraClive G BallardStewart A FactorJoseph H FriedmanAnthony E LangNiccole J LarsenCandace AnderssonDoral FredericksDaniel WeintraubPublished in: Movement disorders : official journal of the Movement Disorder Society (2018)
The antipsychotic effect of pimavanserin is robust in PD patients with cognitive impairment and may be enhanced by concomitant cognitive-enhancing medication use. Future prospective studies are needed to confirm these preliminary findings. © 2018 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.